SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Article citations

More>>

O’Leary, D.A., Noakes, P.G., Lavidis, N.A., Kola, I., Hertzog, P.J. and Ristevski, S. (2007) Targeting of the ETS Factor Gabp Alpha Disrupts Neuromuscular Junction Synaptic Function. Molecular and Cellular Biology, 27, 3470-3480.
http://dx.doi.org/10.1128/MCB.00659-06

has been cited by the following article:

  • TITLE: Gene-Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory

    AUTHORS: Hanan Polansky, Edan Itzkovitz

    KEYWORDS: Gene-Eden-VIR; Microcompetition; Fatigue; Mental Fatigue; Physical Fatigue; Latent; Virus; Human Papillomavirus; HPV; Epstein Barr Virus; EBV; Herpes Simplex Virus; HSV; Cytomegalovirus; CMV; Hepatitis C Virus; HCV

    JOURNAL NAME: Pharmacology & Pharmacy, Vol.5 No.3, March 27, 2014

    ABSTRACT: Objective: The Microcompetition with Foreign DNA theory, proposed by Hanan Polansky in 2003, describes how latent viruses can cause chronic conditions, including fatigue. The Gene-Eden-VIR formula was designed to target latent viruses. Therefore, the theory predicts that treatment with Gene-Eden-VIR will decrease fatigue in individuals infected with a latent virus. The objective of this study was to test this prediction. Framework: A post marketing clinical study that followed FDA guidelines. Treatment: Gene-Eden-VIR, a dietary supplement. A capsule of Gene-Eden-VIR includes 100 mg of quercetin, 150 mg of green tea extract, 50 mg of cinnamon extract, 25 mg of licorice extract, and 100 mcg of selenium. The treatment included 1, 2, 3, or 4 capsules per day, and lasted 2 to 54 weeks. Population: 100 individuals infected with a latent virus, including the Human Papillomavirus (HPV), Epstein Barr Virus (EBV), Herpes Simplex Virus (HSV), Human Cytomegalovirus (HCMV), and Hepatitis C Virus (HCV). Ages ranged from 20 to 66. All participants reported a feeling of fatigue at the start of the study. Specifically, 98, 90, and 79 participants reported a feeling of general, physical, and mental fatigue, respectively. Results: Following treatment with Gene-Eden-VIR, 73.47%, 62.22%, and 47.36% reported a decrease in their feeling of general, physical, and mental fatigue, respectively. The participants also reported a statistically significant decrease in every aspect of fatigue tested in the study. The results also showed a duration effect, that is, those treated for 2 months or more reported a larger decrease in their feeling of fatigue (general, p = 0.03, n = 65; physical and mental, p = 0.05, n = 70). The results showed no interviewer bias, and no selection bias. In addition, the results showed therapeutic consistency under varying manufacturing conditions. The participants reported no side effects after taking Gene-Eden-VIR. Conclusions: This post marketing clinical study showed that treatment with Gene-Eden-VIR safely decreased the feeling of general, physical, and mental fatigue in individuals infected with a latent virus. Since most individuals are infected with a latent virus, health care practitioners should recommend Gene-Eden-VIR as a first line treatment for fatigue. The results of this post marketing clinical study support the Microcompetition with Foreign DNA theory.